1. Home
  2. HAFC vs NGNE Comparison

HAFC vs NGNE Comparison

Compare HAFC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

N/A

Current Price

$32.66

Market Cap

915.9M

Sector

Finance

ML Signal

N/A

Logo Neurogene Inc.

NGNE

Neurogene Inc.

N/A

Current Price

$25.43

Market Cap

744.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HAFC
NGNE
Founded
1982
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
915.9M
744.9M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
HAFC
NGNE
Price
$32.66
$25.43
Analyst Decision
Hold
Strong Buy
Analyst Count
4
10
Target Price
$35.75
★ $77.88
AVG Volume (30 Days)
188.0K
★ 342.8K
Earning Date
10-27-2026
11-20-2026
Dividend Yield
★ 3.44%
N/A
EPS Growth
★ 22.44
0.93
EPS
★ 1.54
N/A
Revenue
★ $270,165,000.00
N/A
Revenue This Year
$10.28
N/A
Revenue Next Year
$5.06
N/A
P/E Ratio
$21.88
★ N/A
Revenue Growth
★ 15.28
N/A
52 Week Low
$24.54
$15.93
52 Week High
$34.46
$43.66

Technical Indicators

Market Signals
Indicator
HAFC
NGNE
Relative Strength Index (RSI) 53.16 47.84
Support Level $30.29 $24.88
Resistance Level $32.99 $28.47
Average True Range (ATR) 0.81 2.50
MACD 0.07 0.38
Stochastic Oscillator 41.82 35.88

Price Performance

Historical Comparison
HAFC
NGNE

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: